Global Pharmaceutical Systems in Social Health Management

The pharmaceutical sector is a cornerstone of modern healthcare systems, yet its global operation remains fragmented and unequally distributed. As the demand for equitable access to medicines grows alongside the vision for universal health coverage (UHC), there is an urgent need to optimize pharmaceutical systems within broader social health management frameworks. Efficient, equitable, and accountable pharmaceutical management is no longer a national concern alone—it is a global imperative shaped by governance, law, regulation, supply chains, and innovation. This article explores the evolving landscape of global pharmaceutical systems and their integration into social health strategies. It highlights pressing challenges and policy innovations in ensuring that essential medicines are not only developed but also accessible, affordable, and appropriately used—especially in low- and middle-income countries. Universal Health Coverage and Medicines as a Social Right The availability of safe, effective, and affordable medicines is fundamental to achieving UHC. However, in many parts of the world, access remains compromised by systemic inefficiencies and regulatory gaps. Wirtz et al. (2020) argue that essential medicines must be recognized as public goods, not commodities, and that their integration into UHC schemes is a litmus test of a government’s commitment to health equity. Singh, Doyle, and Campbell (2021) reinforce this position, noting that without a robust pharmaceutical framework embedded in health policy, UHC becomes symbolic rather than actionable. They emphasize that both price regulation and transparent procurement systems are critical to closing the access gap.